DE60331061D1 - Heterozyklische vegfr-2 kinase inhibitoren - Google Patents

Heterozyklische vegfr-2 kinase inhibitoren

Info

Publication number
DE60331061D1
DE60331061D1 DE60331061T DE60331061T DE60331061D1 DE 60331061 D1 DE60331061 D1 DE 60331061D1 DE 60331061 T DE60331061 T DE 60331061T DE 60331061 T DE60331061 T DE 60331061T DE 60331061 D1 DE60331061 D1 DE 60331061D1
Authority
DE
Germany
Prior art keywords
vegfr
heterocyclic
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331061T
Other languages
German (de)
English (en)
Inventor
Robert M Borzilleri
John S Tokarski
Rajeev S Bhide
Peter Zheng
Ligang Qian
Zhen-Wei Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE60331061D1 publication Critical patent/DE60331061D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60331061T 2002-06-20 2003-06-18 Heterozyklische vegfr-2 kinase inhibitoren Expired - Lifetime DE60331061D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (1)

Publication Number Publication Date
DE60331061D1 true DE60331061D1 (de) 2010-03-11

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331061T Expired - Lifetime DE60331061D1 (de) 2002-06-20 2003-06-18 Heterozyklische vegfr-2 kinase inhibitoren

Country Status (14)

Country Link
US (2) US7084160B2 (enExample)
EP (1) EP1513818B1 (enExample)
JP (1) JP4477492B2 (enExample)
AR (1) AR040272A1 (enExample)
AT (1) ATE455767T1 (enExample)
AU (1) AU2003251559A1 (enExample)
DE (1) DE60331061D1 (enExample)
ES (1) ES2337246T3 (enExample)
IS (1) IS7599A (enExample)
NO (1) NO330043B1 (enExample)
PE (1) PE20040581A1 (enExample)
PL (1) PL374272A1 (enExample)
TW (1) TW200401638A (enExample)
WO (1) WO2004001059A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP2267117A3 (en) * 2002-06-27 2011-07-13 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) * 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2005004864A1 (en) * 2003-07-11 2005-01-20 Merck Patent Gmbh Benzimidazole derivatives as raf kinase inhibitors
DK1684750T3 (da) 2003-10-23 2010-08-09 Ab Science 2-aminoaryloxazol-forbindelser som tyrosinkinase-inhibitorer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
KR20080019578A (ko) * 2005-04-04 2008-03-04 에이비 사이언스 치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
US8337721B2 (en) 2005-12-02 2012-12-25 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
AU2006328882B2 (en) 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA
CA2632924A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Chemical compounds
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
EP2081928B1 (en) 2006-11-10 2014-02-26 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
EP2111402B1 (en) * 2007-01-05 2012-03-07 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
WO2008084103A1 (en) * 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
TWI557111B (zh) 2007-10-26 2016-11-11 加州大學董事會 二芳基乙內醯脲類化合物
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016018795A1 (en) * 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7028766B2 (ja) * 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2332325A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
AU2003221753A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
CA2483164C (en) * 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6951859B2 (en) * 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
TW200401638A (en) 2004-02-01
PE20040581A1 (es) 2004-09-08
US7547711B2 (en) 2009-06-16
ES2337246T3 (es) 2010-04-22
AU2003251559A8 (en) 2004-01-06
US7084160B2 (en) 2006-08-01
JP4477492B2 (ja) 2010-06-09
EP1513818B1 (en) 2010-01-20
JP2005533808A (ja) 2005-11-10
EP1513818A2 (en) 2005-03-16
PL374272A1 (en) 2005-10-03
US20040077696A1 (en) 2004-04-22
AU2003251559A1 (en) 2004-01-06
NO330043B1 (no) 2011-02-07
AR040272A1 (es) 2005-03-23
ATE455767T1 (de) 2010-02-15
US20060135576A1 (en) 2006-06-22
WO2004001059A3 (en) 2004-03-04
IS7599A (is) 2004-12-15
NO20045220L (no) 2005-01-19
EP1513818A4 (en) 2006-10-04
WO2004001059A2 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
ATE455767T1 (de) Heterozyklische vegfr-2 kinase inhibitoren
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
IS7667A (is) Nýjar bensimídazólafleiður
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DK1490355T3 (da) Indolylmaleimidderivater
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602004017623D1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE386518T1 (de) Benzimidazolderivate
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE433449T1 (de) Kinaseinhibitoren
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
ATE366242T1 (de) 5-substituierte chinazolinonderivate
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER
ATE389658T1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
IS7833A (is) Efnasambönd með sameinaða heteróhringi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition